Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAC3tT_djF_2pHZtJwnYceU-f45xWpA9HLcuqB1fyT3qY#assertion>. }

• association type Statement assertion.
• association label "abilify is an atypical antipsychotic indicated as oral formulations for the treatment of schizophrenia 1 1 adults efficacy was established in four 4 6 week trials and one maintenance trial in patients with schizophrenia 14 1 adolescents ages 13 17 efficacy was established in one 6 week trial in patients with schizophrenia 14 1 acute treatment of manic or mixed episodes associated with bipolar i disorder as monotherapy and as an adjunct to lithium or valproate 1 2 adults efficacy was established in four 3 week monotherapy trials and one 6 week adjunctive trial in patients with manic or mixed episodes 14 2 pediatric patients ages 1 17 efficacy was established in one 4 week monotherapy trial in patients with manic or mixed episodes 14 2 maintenance treatment of bipolar i disorder both as monotherapy and as an adjunct to lithium or valproate 1 2 adults efficacy was established in one maintenance monotherapy trial and in one maintenance adjunctive trial 14 2 adjunctive treatment of major depressive disorder mdd 1 3 adults efficacy was established in two 6 week trials in patients with mdd who had an inadequate response to antidepressant therapy during the current episode 14 3 treatment of irritability associated with autistic disorder 1 4 pediatric patients ages 6 17 years efficacy was established in two 8 week trials in patients with autistic disorder 14 4 as an injection for the acute treatment of agitation associated with schizophrenia or bipolar i disorder 1 5 adults efficacy was established in three 24 hour trials in agitated patients with schizophrenia or manic mixed episodes of bipolar i disorder 14 5 abilify is indicated for the treatment of schizophrenia the efficacy of abilify was established in four 4 6 week trials in adults and one 6 week trial in adolescents 13 to 17 years maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents see clinical studies 14 1 acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder both as monotherapy and as an adjunct to lithium or valproate efficacy as monotherapy was established in four 3 week monotherapy trials in adults and one 4 week monotherapy trial in pediatric patients 1 to 17 years efficacy as adjunctive therapy was established in one 6 week adjunctive trial in adults see clinical studies 14 2 maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder both as monotherapy and as an adjunct to either lithium or valproate maintenance efficacy was demonstrated in one monotherapy maintenance trial and in one adjunctive maintenance trial in adults see clinical studies 14 2 abilify is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder mdd efficacy was established in two 6 week trials in adults with mdd who had an inadequate response to antidepressant therapy during the current episode see clinical studies 14 3 abilify is indicated for the treatment of irritability associated with autistic disorder efficacy was established in two 8 week trials in pediatric patients aged 6 to 17 years with irritability associated with autistic disorder including symptoms of aggression towards others deliberate self injuriousness temper tantrums and quickly changing moods see clinical studies 14 4 abilify injection is indicated for the acute treatment of agitation associated with schizophrenia or bipolar disorder manic or mixed psychomotor agitation is defined in dsm iv as excessive motor activity associated with a feeling of inner tension patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care eg threatening behaviors escalating or urgently distressing behavior or self exhausting behavior leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation efficacy was established in three short term 24 hour trials in adults see clinical studies 14 5 psychiatric disorders in children and adolescents are often serious mental disorders with variable symptom profiles that are not always congruent with adult diagnostic criteria it is recommended that psychotropic medication therapy for pediatric patients only be initiated after a thorough diagnostic evaluation has been conducted and careful consideration given to the risks associated with medication treatment medication treatment for pediatric patients with schizophrenia bipolar i disorder and irritability associated with autistic disorder is indicated as part of a total treatment program that often includes psychological educational and social interventions" assertion.
• association subject drugbank:DB01238 assertion.
• association predicate treats assertion.
• association object DOID_12849 assertion.
• association relation SymptomaticReliefIndication assertion.
• DOID_12849 category Disease assertion.
• drugbank:DB01238 category Drug assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
• association provided_by NeuroDKG assertion.